Commentary · 8 Oct 2025
Research articlePublished 2015
Efficacy and Safety of Tenofovir and Lamivudine in Late Pregnancy for Preventing Perinatal Transmission of Hepatitis B Virus in Highly Viremic Mothers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Chronic hepatitis B virus (HBV) infection early in the life confers a high risk of chronicity, particularly in children born to highly viremic mothers, due to “viral vaccine breakthrough” phenomenon that could be treated by antivirals such as lamivudine and recently tenofovir. Objective: We evaluated efficacy and safety of lamivudine and tenofovir in late pregnancy in preventing perinatal transmission of hepatitis B virus (HBV) to infants born to highly viremic mothers. Materials and Methods: A total of 82 pregnant chronic HBsAg+ women with high viremia (>107 copies/mL) at 32 weeks of gestation were randomly assigned to 2 groups (lamivudine 100 mg or tenofovir 300 mg daily from 8 weeks of prepartum to week 4 postpartum). Infants received recombinant HBV vaccine without HBIg and were followed until week 52. Results: HBV perinatal trasmission rate, defined by HBsAg presence in children’s blood at week 52, was only 1.2% (1/82). The mean maternal viral load sharply decreased from 5.09 x 108 ± 3.19 x 108 copies/mL at week 32 of gestation to 1.13 x 106 ± 3.91 x 106 at labor (p<0.001). The viral load reduction was stronger in tenofovir-treated mothers than in lamivudine-treated ones (p<0.028), particularly in 4 log10 reduction (p<0.001). No viral resistance to the drugs was noted. Drug adverse events were rare and transient, allowing complete full course in all cases, and flare was seen in no case. Conclusion: Both lamivudine and tenofovir exhibited a high efficacy in preventing mother-to-child perinatal transmission of HBV and a good safety without viral resistance.
Keywords
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Annals of Clinical and Laboratory Research.
Mini review · 2 Oct 2025
Characteristics and Treatment of Juvenile Myasthenia Gravis
Commentary · 9 Jul 2025
Commentary on Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: Real-World Data from 134 Patients
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Clinical and Laboratory Research
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Nguyen Van Bang”
- BylineArticles whose byline prints “Le Thi Lan Anh”
- BylineArticles whose byline prints “Nguyen Thi Van Anh”
- BylineArticles whose byline prints “Nguyen Th Quynh Mai”
- BylineArticles whose byline prints “Vu Tuong Van”
- BylineArticles whose byline prints “Sofiane Mohamed”
- BylineArticles whose byline prints “Philippe Halfon”
- BylineArticles whose byline prints “Marc Bourli?re”
